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Abstract Raloxifene (RLX) is an oral selective estrogen receptor modulator 
(SERM). It is showing estrogenic action on bone and anti-estrogenic action on 
uterus and breast. An extensive literature has been published for analysis of 
RLX in different pharmaceutical formulations. This review article endeavor to 
provide the detail account on analytical methods for RLX and also validation 
details for its readers. It further helps to avoid costly chemicals and time 
consuming exercises for further investigation of RLX.
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1. INTRODUCTION
Raloxifene (RLX) is an oral selective estrogen receptor modulator (SERM). 
It is showing estrogenic action on bone and anti-estrongenic action on uterus 
and breast.RLX is chemically[6- hydroxy-2-(4-hydroxyphenyl)benzo[b]thien-
3-yl] -[4-[2-(1-piperidinyl) ethoxy] phenyl] Methanone (Figure 1). It belongs 
to benzothiophene derivative. RLX is used in the treatment and prevention of 
osteoporosis in post-menopausal women by reducing resorption of bone and 
increasing bone mineral density. [1] This effect is produce by ERα & ERβ 
receptor where it acts as partial agonist. RLX is preferred drug in the treatment 
of breast cancer because of its antagonist action at this site. [2]
Analytical chemistry deals with the techniques for separation, 
identification and also for quantification of chemical component such as 





based on much contemplation which includes chemical properties of analyte, 
its concentration, cost of analysis and also on the type of estimation either 
qualitative or quantitative.
A qualitative technique gives knowledge about the chemical identity of 
the species in the sample. A quantitative technique gives numerical data about 
one or more analyte in the matrix sample.The most explored techniques for 
quantitative analysis of drugs and its metabolite in blood sample includes High-
Performance Liquid-Chromatography (HPLC), Thin–Layer Chromatography 
(TLC) and also hyphenated techniques such as LC-MS, LC-MS-MS, LC-
NMR etc [4, 5] 
The review article attempts to compile the date of methods applied for analysis 
of RLX in bulk, pharmaceutical formulation and biological matrix. Further the 
discussion about some prominently applied analytical methods is also included.
2. ANALYTICAL ESTIMATION OF RLX
The analysis of drugs is an inclusive part of drug development process.RLX 
is official in Indian pharmacopoeia and suggested the RP-HPLC method by 
applying stainless steel column 150 × 4.6 cm packed with octylsilane bonded 
to porous silica (3.5 µm) and acetonitrile and phosphate buffer (33:67 v/v) pH 
of the resulting solution was maintain at 2.5 which was adjusted by aqueous 
solution of potassium hydroxide or orthophosphoric acid. The RLX was 
detected done by spectrophotometer at 280 nm.[6]
 Figure1: 2D Structure of RLX.
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2.1 Spectrophotometry/ Spectroscopy Methods for Analysis of RLX
In most of these UV- Spectrophotometricmethods, Methanol and NaOH 
(0.1N )were used as a solvent. In methanol and NaOH (0.1 N) solvents 
RLX exhibitabsorbance maximumat 289 nm and 303 nm, respectively.
The bathochromic shift in wavelength of absorbance maximum for RLX in 
0.1NaOH may be due to solvent effect. The valued information about these 
methods viz solvent used, detection wavelength linearity and range, coefficient 
correlation value has been furnished in Table 1. [7–15]
2.2 Colorimetric Methods
Four Colourimetric methods have been studied for analysis of RLX. A colour 
chromogen of RLX was formed by reacting it with different reagents. The 





























AUC 275 – 350
First 
Order 303-385
4 Tablet Zero Order 288 2–12 0.999 Methanol 10
5 Tablet Zero Order
665 0.5 – 5.0 0.9997 Distilled water 11555 – 2.0
6 Tablet Zero Order 649.3 10 – 30 0.9998 Methanol 12
7 Tablet Zero Order
520 0.1–2.0 0.9993 Water 13610 0.5 – 6.0 0.9989
8 Tablet Zero Order 624.4 16 – 48 0.9999 Methanol 14






intensity of colour was recorded at the appropriate wavelength. The details 
about the methods are given in Table 2.
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 B. Kalyanaramu et al. established a simple and easy method for 
quantification of RLX in bulk and pharmaceutical preparations by visible 
spectrophotometry. Analytical method illustrated for RLX was suggested to 
be depend on creation of dark green colored chromogen complex with sodium 
nitroprusside in presence of hydroxyl amine under alkaline conditions. The 
detection of RLX was performed at wavelength 720 nm. The developed method 
was implemented for analysis of RLX in pharmaceutical formulation. The 
author depicted the mechanism for the formation of the colored chromogen. 
RLX is acting as a donor because of availability of cyclic tertiary nitrogen in 
piperidine portion and sodium nitroprusside in occurrence of hydroxylamine 
and alkali exists as aquoferrocyanide [Fe (CN) 5H2O]
3-.The mechanism of 
formation of colour chromogen is depicted in Figure 2. [16]
2.3 Differential Spectrophotometry Method
One method was reported using differential Spectrophotometry technique. Two 
different solutions of RLX were prepared using HCl(0.1 N)and NaOH (0.1N). 
These solutions further diluted with the respective solvents and scanned in the 
UV- range. RLX in HCl (0.1 N)exhibited maximum absorbance at 289 nm 
whereas in NaOH (0.1 N) it exhibited absorbance at 333.4 nm. The difference 
absorption spectrum (ΔA) of alkaline RLX was measured using basic solution 
in sample cell and acidic solution in reference cell.[21]





2.4 Reversed-Phase High-Performance Liquid Chromatography (RP-
HPLC)
Currently RP-HPLC is the most explored analytical tool for separating complicated 
mixture of chemical, pharmaceutical and biotechnology industry. RP-HPLC is 
the opposite to normalphasechromatography. In RP-HPLC the stationary phase 
is nonpolar and mobile phase is polar. The most common stationary phases used 
is octadecyldimethyl (C18) with silicaas the solid support. Silica has a narrow pH 
range (3–8) where mixtures of component can be separated without deteriorating 
the column performance. Above pH 8, these columns are not suitable due to 
dissolving of silica and it may damage the column. Below pH 3, the silicon-carbon 
bond is broken and the column be damaged.Theseparation is attend byanalytes 
having different interactions with the stationary phase. In RP-HPLC,solutes are 
resolved on the basis of their hydrophobicity. A highly hydrophobic solute will 
beretained on the column for longer period of time than a less hydrophobic one. 
Further, polar solutes will interact withthe silica surface to cause peak tailing. 
The mobile phase is one of the two components involvedin the resolution. Water 
is generally one of the components of a binary mixture in RP-HPLC.Water is 
considered to be the weak portion of the mobile phase and does not interactwith 
the hydrophobic stationary phase.[22– 33]
Thirteen RP-HPLC methods have been studied for analysis of RLX in 
pharmaceutical matrix . In many of these methods UV- visible detector and 
Diode array detector has been implemented. Overall ten methods have implanted 
isocratic mode for analysis of RLX and only three methods reported gradient mode 
of analysis. The details about the mobile phase composition columns, detector, 
Detection and linearity, validation parameters etc. are summarized in Table3.
2.5. Determination of RLX and its Impurities 
Impurity profiling is of great significance in novel drug substance and new 
drug product due to their potential undesirable pharmacological effects., 
possible toxicity, adverse effects. Ultimately it has large impact on the activity, 
efficacy and the stability of drug substance and its bioavailability. So there is 
enduring requirement for establishing new simple accurate, specific methods 
for estimation of drug impurities. There are various sources of impurities; they 
are from starting material; intermediates and by-product from the synthesis 
of active pharmaceutical ingredient( Process related impurity); degradation 
product emerged during manufacturing process and also through storage of 
product for longer period; and also interaction product between API and other 
active ingredients and excipients or primary container . [34-36] Very few 
research papers are reported on impurity profiling of RLX. 
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European pharmacopoeia reported three impurities mainly along 






oxide(impurity 3)[37]. The impurity 1 is also reported in United States 
Pharmacopeia.[38]
Improvement in optimization of separation of impurities is achieved by 
recently established chromatographic techniques, applications of it liquid 
chromatography- separation of RLXand itsimpurities have beenstudied.
Research paper explored about the chromatographic separation of RLX and 
its impurities using analytical column was x BridgeTM 100 mm x 3 mm, 3.5 
µm particle size columns. Acetonitrile: Water ( 5 mM-SDS, pH 2.8) mixture 
of 45:55% v/v was selected as a mobile phase and detection of drug and 
impurities were performed at 254 nm with flow rate 1mL / min. 
The central composite design experimental plan using new chromatographic 
response function ( CRF) was the major outcome of the system. [39] 
N. Jagdeesh et al reported structural interpretation of the most potent 
impurities of RLX by LC/ESI-MS and NMR. Three impurities were detected 
during the impurity profile studies of RLX by reversed phase gradient HPLC 
method. These three impurities displayed identical molecular ion at m/z488. 
[40]
R.B. Reddy et al established detection and characterization of potent 
impurities in RLX. At the time of synthesis of the bulk drug RLX, eight 
impurities were reported. Out of which four were reported to be new. All these 
impurities identified using gradient high performance liquid chromatography 
method. LC-MS was studied to detect the mass number of the these impurities 
and systematic protocol was followed to characterize them. These impurities 
were also synthesized and characterized. Further the confirmation has been 
done by co- injecting the synthesized impurities with the RLX in HPLC. 
The confirmation has been done on the basis of matching the spectral and 
chromatographic data. [41] 
Out of eight reported impurities, three are already reported in 
European pharmacopoeia. [37] The chemical name of remaining impurities 
[6,6’-Dihydroxy-2,2’-bis(4-hydroxyphenyl)-7,7’-bi-1-benzothiophene-
3,3’-diyl]bis{[4-(2-piperdin-1-ylethoxy)phenyl]methanone}(impurity4); 
6-Acetoxy-2-[4-hydroxyphenyl]-0-benzothiophene (impurity 5); Methyl 





hydroxyphenyl)-1-benzothiophen-3-yl]ethanone (impurity 7); 7-Acetyl-[6 
hydroxy-2-(4-hydroxyphenyl)-1-benzothiophen-3-yl][4-[2-(piperidin-1-yl)
ethoxy]phenyl methanone (impurity 8)The chemical structures of impurities 
1- 8 in RLX is shown in (Figure 3).
2.6 Bio-analytical Method
Bio-analytical method is one of the most useful method for the estimation of 
RLX in biological sample like tissue, Human plasma etc.A most advanced 
high throughput assay protocal was studied for quantification of tamoxifene, 
iodoxifene and raloxidene in human plasma with LC-MS/MS. Raloxifene was 
reported to impact on estrogen receptor activity in human skeletal muscle cells 
and may add benefits to muscle function. But the 
It was also recommended that raloxifene might increase performance in 
athletes. But, raloxifene in urine sample of athletes has never been detected 
in annual overview of analytical results published by anti-doping laboratories 
published by WADA during 2003 to 2010. 
Reports suggested few analytical methods such as LC-MS-MS for 
detection of raloxifene.
Most of these analytical methods are cumbersome and time consuming.
The present review revealed the LC- MS method used for the determination of 
RLX. This is summarized in Table 4.
Table 3: RP-HPLC Methods for Analysis of RLX in Pharmaceutical dosage 
form.
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Table 4: Bioanalytical LC-MS/MS Method.
Sr.
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LC-MS method for estimation of RLX and its metabolite in human 
plasma has been studied. Two main glucuronide metabolite, raloxifene 
-6-glucuronide (M1) and raloxifene-4- glucuronide (M2) in human plasma 






















































254 3-11 µg/ml 0.83 0.996 51
2.7. Capillary Electrophoresis
The migration nature of raloxifene was explored by capillary electrophoresis 
(CE). The influence of various parameters such as nature and concentration of 
the running buffer, pH and applied voltage on migration time, peak symmetry 
and efficiency was thoroughly investigated. 20mM acetate buffer of pH 4.5 
was found to give a very stable electrophoretic system for the analysis of 
raloxifene. The plasma sample were also investigated by applying HPLC 
Beckman Coulter( Fullerton CA, USA) instrument. The chromatography 
was studied on a 5 um utrasphere C18 column using acetonitrile/10mM SDS 
(11.9, pH 7) and detection was done at 286 nm. [47]
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2.8. Stability–Indicating Method (SIM) used for determination of RLX
Stability- indicating methods are quantitative test methods that can identify 
change in API and drug products throughout the time and under certain 
conditions. Food and Drug Administration (FDA), European Medicine 
Agency, other regulatory agencies, ICH and good manufacturing practices 
need establishment and validation of stability indicating method. 
Five stability indicating methods have studied so far for determination of 
RLX in pharmaceutical formulation. The details about the stability indicating 
methods are summarized in Table 5. 
CONCLUSION
The present review gives detailed account on analytical methods explored for 
the analysis of RLX. Various analytical techniques have been studied includes 
HPLC, HPTLC, Capillary electrophoresis, LC-MS for estimation of RLX in 
pharmaceutical formulation and biological fluids. Liquid chromatography 
with UV detection has been the most explored technique for quantification of 
RLX and RLX impurities in bulk as well as in pharmaceutical dosage form. 
Hyphenated technique such as LC-MS, LC-MS/MS are studied for estimation 
of RLX and its metabolite in human plasma. Few other methods such as HPLC, 
HPTLC and capillary electrophoresis have also been studied. 
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